Hemostatic and Inflammatory Biomarkers Associated with Suspected Restenosis after Percutaneous Coronary Intervention in Type 2 Diabetes

type 2 diabetes mellitus percutaneous coronary intervention suspected in-stent restenosis D-dimer fibrinogen hs-CRP IL-6 risk stratification

Authors

  • Rakhimov, N. A. Head of the Cardiology Department, Bukhara Regional Multidisciplinary Medical Center; Independent Researcher, Bukhara State Medical Institute, Bukhara, Uzbekistan
November 2, 2026

Downloads

Background: Diabetes-associated metabolic and inflammatory disturbances may contribute to recurrent coronary narrowing after percutaneous coronary intervention (PCI). Objective: To describe the distribution of hemostatic, metabolic, and inflammatory biomarkers in a previously reported clinical series stratified by suspected post-PCI restenosis. Methods: This descriptive manuscript is based on aggregate results reported from a 2022–2024 single-center cohort comprising 110 patients undergoing PCI and 30 apparently healthy comparators. Reported biomarkers included glycated hemoglobin (HbA1c), D-dimer, fibrinogen, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and HOMA-IR. Results: Suspected restenosis was reported in 42/110 patients (38.2%). Compared with the group without suspected restenosis, the suspected-restenosis group showed higher HbA1c (8.9 ± 1.1% versus 7.4 ± 0.8%), D-dimer (1.62 ± 0.41 versus 0.72 ± 0.19 μg/mL), and hs-CRP (6.9 ± 2.0 versus 3.8 ± 1.2 mg/L). Reported apparent ROC areas were 0.89 for D-dimer, 0.86 for fibrinogen, and 0.83 for hs-CRP; these estimates could not be independently verified. Conclusion: The reported biomarker patterns support further evaluation of integrated risk stratification, but diagnostic adjudication, patient-level analysis, and external validation are prerequisites to clinical deployment.